Carrying out intended dosing regimens often require highly concentrated protein formulations that may be too viscous for subcutaneous administration or other routes of administration that are limited by volume. While reducing viscosity with a single excipient can be ineffective or compromising protein stability, our platform featuring combinations of viscosity-reducing agents provides a variety of manufacturing and final formulation benefits.
Our Viscosity Reduction Platform enables subcutaneous formulation of highly concentrated protein biologics, bringing together increased concentrations and improved downstream processing.
Our offering comprises:
Do you have a viscosity issue but no resources to test the platform? We offer support via our Feasibility Testing Service:
The result: subcutaneous administration of protein-based therapeutics to improve patient compliance and help avoid hospitalization.